Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (FY)Aug 31, 2025 | (Q4)Aug 31, 2025 | (Q3)May 31, 2025 | (Q2)Feb 28, 2025 | (Q1)Nov 30, 2024 | (FY)Aug 31, 2024 | (Q4)Aug 31, 2024 | (Q3)May 31, 2024 | (Q2)Feb 29, 2024 | (Q1)Nov 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -206.54%-1.42M | -2,695.49%-398.61K | -26.78%-408.21K | -1,074.60%-367.24K | -156.43%-243.07K | 73.10%-462.29K | 97.72%-14.26K | -161.17%-321.98K | 94.56%-31.27K | 90.93%-94.79K |
| Net income from continuing operations | -9.97%-4.86M | 16.14%-2.37M | -130.63%-984.33K | -18.06%-703.03K | -40.95%-800.63K | 6.09%-4.42M | -105.72%-2.83M | -36.75%-426.8K | 40.57%-595.47K | 71.84%-568.03K |
| Operating gains losses | 130.56%159.87K | 235.98%385.4K | 3.10%-217.86K | 66.66%-5.44K | -265.43%-2.23K | 17.67%-523.2K | 54.02%-283.41K | -1,648.48%-224.84K | -6.73%-16.3K | -85.01%1.35K |
| Depreciation and amortization | --0 | --0 | --0 | --0 | --0 | 93.86%84.71K | --0 | 62.85%28.24K | 5,062.16%28.24K | 2,214.43%28.24K |
| Asset impairment expenditure | --0 | ---- | ---- | ---- | ---- | 292.77%2.61M | ---- | ---- | ---- | ---- |
| Remuneration paid in stock | 93.88%527.12K | 145.12%267.45K | -43.04%33.46K | -32.20%39.55K | 308.46%186.67K | -9.91%271.88K | -15.26%109.11K | -23.57%58.74K | -25.27%58.33K | 152.39%45.7K |
| Other non cashItems | 219.63%596.57K | 86.91%197.12K | 287.40%141.77K | 501.87%134.51K | 453.82%123.16K | -83.00%186.65K | 130.96%105.46K | 1,146.46%36.6K | 9.52%22.35K | -97.84%22.24K |
| Change In working capital | 62.56%2.16M | 307.73%1.13M | 200.23%618.75K | -64.55%167.17K | -33.47%249.96K | -12.33%1.33M | -48.34%275.93K | -71.52%206.09K | 37.35%471.6K | 543.61%375.72K |
| -Change in receivables | -784.80%-38.16K | -12,795.77%-42.69K | --0 | 246.10%10.09K | -146.98%-5.56K | 65.49%5.57K | 88.43%-331 | -96.10%974 | -185.76%-6.9K | 172.40%11.83K |
| -Change in inventory | --0 | --0 | --0 | --0 | --0 | -92.65%1.76K | -99.99%2 | --0 | --0 | --1.76K |
| -Change in prepaid assets | -92.11%10.71K | --36.26K | -111.86%-17K | --0 | 66.85%-8.55K | 466.12%135.72K | --0 | -23.64%143.35K | -59.07%18.14K | 87.31%-25.77K |
| -Change in payables and accrued expense | 84.47%2.19M | 309.57%1.13M | 929.35%635.75K | -65.88%157.08K | -31.93%264.06K | -22.27%1.19M | -80.57%276.26K | 118.61%61.76K | 52.72%460.36K | 188.02%387.9K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -206.54%-1.42M | -2,695.49%-398.61K | -26.78%-408.21K | -1,074.60%-367.24K | -156.43%-243.07K | 73.10%-462.29K | 97.72%-14.26K | -161.17%-321.98K | 94.56%-31.27K | 90.93%-94.79K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -1.69M | 0 | ||||||||
| Net investment purchase and sale | ---1.69M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | ---1.69M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 1,454.48%8.76M | -97.48%5.69K | 2,364.48%8.33M | -40.68%563.51K | 1,912.19%225.71K | 505.68%337.8K | ||||
| Net issuance payments of debt | -70.03%168.87K | -105.04%-11.37K | ---- | ---- | ---- | 67.21%563.51K | --225.71K | 404.26%337.8K | ---- | ---- |
| Net common stock issuance | --345.53K | --96.86K | --0 | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| Proceeds from stock option exercised by employees | ---- | ---- | ---- | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| Net other financing activities | --8.25M | ---79.8K | --8.14M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 1,454.48%8.76M | -97.48%5.69K | 2,364.48%8.33M | ---- | ---- | -40.68%563.51K | 1,912.19%225.71K | 505.68%337.8K | ---- | ---- |
| Net cash flow | ||||||||||
| Beginning cash position | 69.49%237.77K | 26,877.07%7.97M | 379.01%24.29K | -45.13%25.55K | 69.49%237.77K | -84.54%140.29K | -96.09%29.54K | -97.06%5.07K | -89.64%46.56K | -84.54%140.29K |
| Current changes in cash | 5,487.95%5.66M | -1,083.51%-2.08M | 49,946.10%7.92M | 297.27%61.68K | -156.43%-243.07K | 113.17%101.21K | 134.43%211.45K | -97.28%15.82K | 88.77%-31.27K | 79.31%-94.79K |
| Effect of exchange rate changes | -956.89%-39.44K | -973.39%-34.49K | 213.83%27.14K | -515.38%-62.94K | 2,807.26%30.85K | -369.65%-3.73K | -630.23%-3.21K | 4,524.60%8.65K | -724.80%-10.23K | --1.06K |
| End cash Position | 2,362.07%5.85M | 2,362.07%5.85M | 26,877.07%7.97M | 379.01%24.29K | -45.13%25.55K | 69.49%237.77K | 69.49%237.77K | -96.09%29.54K | -97.06%5.07K | -89.64%46.56K |
| Free cash from | -206.54%-1.42M | -2,695.49%-398.61K | -26.78%-408.21K | -1,074.60%-367.24K | -156.43%-243.07K | 73.10%-462.29K | 97.72%-14.26K | -161.17%-321.98K | 94.56%-31.27K | 90.93%-94.79K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.